Canada’s hopes of speeding up COVID-19 vaccinations brightened slightly over the weekend as regulators began work to approve a new inoculation, even as the federal government sought to head off any restrictions on vaccine shipments from Europe.
Pharmaceutical company Novavax quietly submitted its COVID-19 vaccine to Health Canada for regulatory approval on Friday, less than two weeks after Ottawa finalized a deal with the Maryland-based company for 52 million doses of the shot.
Because of the emergency nature of the pandemic, Health Canada is accepting applications for vaccines before the final trial data is ready, allowing the review team to start poring over the documents on an ongoing basis rather than waiting until everything is finished.
The rolling review allows for much faster approval once the final results from clinical trials are complete.
Novavax is the fifth vaccine maker to submit an application for rolling review. AstraZeneca, Pfizer-BioNTech and Moderna all submitted in early October; Johnson and Johnson followed suit at the end of November.
Health Canada approved the Pfizer-BioNTech vaccine on Dec. 9 and gave Moderna the green light on Dec.
A decision on AstraZeneca is expected in the next couple of weeks.
Johnson and Johnson reported results from its Phase 3 trial just last week.
Novavax also reported results Thursday from a trial in the United Kingdom, but a large trial in the U.S. is still at least a month or two away from yielding final results.
Novavax has said its vaccine was 89 per cent effective in the U.K. trial. It also touts its product as very effective against the two coronavirus variants first detected in the U.K. and South Africa.
Johnson and Johnson’s long-awaited COVID-19 vaccine appears to protect against symptomatic illness with just one shot, although it’s not as strong as some two-shot rivals. (AP)
Application comes as Ottawa faces criticism over vaccine rollout
Novavax’s application comes as the federal Liberal government faces withering criticism for the pace of vaccinations across the country, with opposition parties and some provincial governments complaining about a lack of shots.
Those critiques have come as Pfizer slows delivery of its vaccines to Canada so it can expand a production plant in Belgium.
(Francisco Seco/Associated Press)
Ng was told the same thing during her phone call with Valdis Dombrovskis, the European Commission’s commissioner for trade, according to a summary of their conversation provided by Global Affairs Canada.
“I was really clear that Canada’s expectation is that our purchase contracts with the vaccine makers are not disrupted,” Ng said in a Sunday interview on Rosemary Barton Live. “I would note that in their regulation, there is absolutely consideration for advance purchase agreements that have been made, like that of Canada, with the vaccine makers, and our expectation is that there is no disruption or delay.
Ng also told CBC Chief Political Correspondent Rosemary Barton that Ottawa is taking a “whole of government approach” to tackle the issue.
“Minister Garneau has already spoken to some of his counterparts and continues that work, as will Minister Hajdu,” she said. “Minister Anand, of course, is in constant contact with the suppliers, and I have been speaking to my international counterparts.”
Threat of vaccine nationalism reinforces global need for better pandemic planningOttawa urged by member of COVID-19 task force to ramp up vaccine manufacturing in this country
Von der Leyen said Friday the commission is following through on a threat to force COVID-19 vaccine makers to show them what vaccines they are producing in Europe and where those are going.
She said the export transparency rule is temporary but has to be done as the continent is in an ongoing battle with vaccine-makers about slow deliveries.
Both Pfizer-BioNTech and AstraZeneca are behind on their scheduled deliveries to European nations, but it is the latter with which Europe is having the loudest fight.
The EU is demanding the company ship doses made in the U.K.